AnGes, Inc.
4563
Rank in Stocks
#21575
AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and... AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and established in 1999, focuses on pioneering the research and development of gene-based medical solutions. Its primary therapeutic asset is Hepatocyte Growth Factor (HGF) Plasmid, an innovative gene therapy designed to address critical limb ischemia, a severe circulatory condition impacting the legs. The company's diverse pipeline also includes NF-kB Decoy Oligonucleotide, a nucleic acid medicine formulated to suppress inflammation for various ailments, including low back pain. Furthermore, AnGes is actively developing treatments for atopic dermatitis and disc degeneration, as well as specialized medical devices aimed at preventing vascular restenosis. Their development endeavors also extend to therapeutic vaccines for cervical intraepithelial neoplasia, a precursor to cervical cancer, and, through a research partnership with Osaka University, DNA vaccines targeting hypertension. AnGes fosters strategic alliances to expand its global reach and product commercialization. These collaborations include BioMarin Pharmaceutical Inc. for the Japanese market distribution of Naglazyme, a drug for mucopolysaccharidosis VI; and Mitsubishi Tanabe Pharma Corporation, which handles the marketing of HGF Plasmid for peripheral arterial disease in both the United States and Japan. Other key partners are SHIONOGI & CO., LTD. for the commercialization of topical NF-kB decoy oligonucleotide drugs for dermatological conditions, and Vical, Inc. for the development and marketing of Allovectin, a cancer treatment. Additionally, AnGes has joined forces with Osaka University to develop a coronavirus vaccine, and with Brickell Biotech, Inc. for an investigational plasmid DNA vaccine intended to prevent coronavirus across the U.S., South America, and other territories. The company, previously known as AnGes MG, Inc., officially rebranded to AnGes, Inc. in July 2017.
Share Price
$0.16457103
Last synced: 2026-11-10
Market Cap
$65.64M
Change (1 day)
-3.70%
Change (1 year)
-66.64%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade AnGes, Inc. (4563)
Category
Healthcare
EPS for AnGes, Inc. (4563)
EPS as of June 2026 TTM: $-0.06
According to AnGes, Inc.'s latest financial reports, its current EPS (TTM) is $-0.06. At the end of 2025 the company had an EPS of $-0.09, an increase over its 2024 EPS of $-0.76.
EPS history for AnGes, Inc. from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.06 | -32.89% |
| 2025 | $-0.09 | -87.92% |
| 2024 | $-0.76 | 173.26% |
| 2023 | $-0.28 | -61.26% |
| 2022 | $-0.72 | -10.86% |
| 2021 | $-0.81 | 135.74% |
| 2020 | $-0.34 | 3.85% |
| 2019 | $-0.33 | 4.84% |
| 2018 | $-0.31 | -28.29% |
| 2017 | $-0.44 | -31.92% |
| 2016 | $-0.64 | 3.97% |
| 2015 | $-0.62 | 19.38% |
| 2014 | $-0.52 | 16.43% |
| 2013 | $-0.45 | -32.85% |
| 2012 | $-0.66 | -19.05% |
| 2011 | $-0.82 | -5.83% |
| 2010 | $-0.87 | -23.17% |
| 2009 | $-1.13 | -19.39% |
| 2008 | $-1.41 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -26,027.15% |
US
|
|
| $-7.07 | 11,605.30% |
US
|
|
| $-5.29 | 8,658.28% |
AU
|
|
| $12.88 | -21,424.67% |
BE
|
|
| $21.56 | -35,795.36% |
NL
|
Questions about AnGes, Inc.'s earnings per share (EPS)
What is AnGes, Inc.'s earnings per share (EPS)?
AnGes, Inc.'s earnings per share (EPS) over the last twelve months is $-0.06, as of Jun 2026.
What was AnGes, Inc.'s earnings per share (EPS) in 2025?
In 2025, AnGes, Inc.'s earnings per share (EPS) was $-0.09, compared with $-0.76 in 2024.
How has AnGes, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, AnGes, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.09) and lowest in 2021 ($-0.81).
How does AnGes, Inc.'s earnings per share (EPS) compare with similar companies?
AnGes, Inc.'s earnings per share (EPS) ($-0.06) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.